AU763049B2 - Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors - Google Patents
Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors Download PDFInfo
- Publication number
- AU763049B2 AU763049B2 AU23942/00A AU2394200A AU763049B2 AU 763049 B2 AU763049 B2 AU 763049B2 AU 23942/00 A AU23942/00 A AU 23942/00A AU 2394200 A AU2394200 A AU 2394200A AU 763049 B2 AU763049 B2 AU 763049B2
- Authority
- AU
- Australia
- Prior art keywords
- aav
- treating
- vector
- therapeutically
- associated virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000004413 cardiac myocyte Anatomy 0.000 title claims description 51
- 108090000623 proteins and genes Proteins 0.000 title claims description 47
- 239000013598 vector Substances 0.000 title claims description 38
- 238000001727 in vivo Methods 0.000 title claims description 9
- 238000012546 transfer Methods 0.000 title description 7
- 241000700605 Viruses Species 0.000 title description 6
- 238000000034 method Methods 0.000 claims description 35
- 230000037396 body weight Effects 0.000 claims description 30
- 102000004169 proteins and genes Human genes 0.000 claims description 30
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 28
- 150000007523 nucleic acids Chemical class 0.000 claims description 24
- 241000702421 Dependoparvovirus Species 0.000 claims description 23
- 108020004707 nucleic acids Proteins 0.000 claims description 23
- 102000039446 nucleic acids Human genes 0.000 claims description 23
- 230000033115 angiogenesis Effects 0.000 claims description 22
- 210000004351 coronary vessel Anatomy 0.000 claims description 22
- 238000001802 infusion Methods 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 210000003748 coronary sinus Anatomy 0.000 claims description 11
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 9
- 206010019280 Heart failures Diseases 0.000 claims description 9
- 239000002870 angiogenesis inducing agent Substances 0.000 claims description 9
- 206010003119 arrhythmia Diseases 0.000 claims description 9
- 210000001367 artery Anatomy 0.000 claims description 9
- 230000001939 inductive effect Effects 0.000 claims description 9
- 208000037803 restenosis Diseases 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 206010048858 Ischaemic cardiomyopathy Diseases 0.000 claims description 8
- 230000006793 arrhythmia Effects 0.000 claims description 8
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 230000003211 malignant effect Effects 0.000 claims description 8
- 230000004936 stimulating effect Effects 0.000 claims description 7
- 108020005544 Antisense RNA Proteins 0.000 claims description 6
- 239000003184 complementary RNA Substances 0.000 claims description 6
- 206010056370 Congestive cardiomyopathy Diseases 0.000 claims description 5
- 201000010046 Dilated cardiomyopathy Diseases 0.000 claims description 5
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 5
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 5
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 5
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 5
- 239000003102 growth factor Substances 0.000 claims description 5
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 239000013607 AAV vector Substances 0.000 claims description 4
- 108060003345 Adrenergic Receptor Proteins 0.000 claims description 4
- 102000017910 Adrenergic receptor Human genes 0.000 claims description 4
- 108010068426 Contractile Proteins Proteins 0.000 claims description 4
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 claims description 4
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 claims description 4
- 102100032742 Histone-lysine N-methyltransferase SETD2 Human genes 0.000 claims description 4
- 101000654725 Homo sapiens Histone-lysine N-methyltransferase SETD2 Proteins 0.000 claims description 4
- 108090000862 Ion Channels Proteins 0.000 claims description 4
- 102000006601 Thymidine Kinase Human genes 0.000 claims description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims description 4
- 230000001800 adrenalinergic effect Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 108010059929 phospholamban Proteins 0.000 claims description 4
- 102000005681 phospholamban Human genes 0.000 claims description 4
- 238000011161 development Methods 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 102000002585 Contractile Proteins Human genes 0.000 claims 3
- 102000004310 Ion Channels Human genes 0.000 claims 3
- 102000001253 Protein Kinase Human genes 0.000 claims 3
- 108060006633 protein kinase Proteins 0.000 claims 3
- 108700026220 vif Genes Proteins 0.000 claims 3
- 102000003945 NF-kappa B Human genes 0.000 claims 2
- 108010057466 NF-kappa B Proteins 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 1
- 239000013608 rAAV vector Substances 0.000 description 20
- 230000014509 gene expression Effects 0.000 description 18
- 238000010361 transduction Methods 0.000 description 16
- 230000026683 transduction Effects 0.000 description 16
- 108700019146 Transgenes Proteins 0.000 description 15
- 230000000747 cardiac effect Effects 0.000 description 11
- 230000010412 perfusion Effects 0.000 description 11
- 241001465754 Metazoa Species 0.000 description 8
- 238000001415 gene therapy Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- 210000005003 heart tissue Anatomy 0.000 description 7
- 208000015181 infectious disease Diseases 0.000 description 7
- 210000004165 myocardium Anatomy 0.000 description 7
- 241000701161 unidentified adenovirus Species 0.000 description 7
- 230000002107 myocardial effect Effects 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003612 virological effect Effects 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 108020004414 DNA Proteins 0.000 description 3
- 241000283984 Rodentia Species 0.000 description 3
- 230000003872 anastomosis Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 230000002458 infectious effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000009525 Myocarditis Diseases 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 241000714474 Rous sarcoma virus Species 0.000 description 2
- 241000282887 Suidae Species 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 230000003527 anti-angiogenesis Effects 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000010009 beating Methods 0.000 description 2
- 210000001715 carotid artery Anatomy 0.000 description 2
- 210000001168 carotid artery common Anatomy 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 230000008488 polyadenylation Effects 0.000 description 2
- 210000002027 skeletal muscle Anatomy 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 210000004509 vascular smooth muscle cell Anatomy 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 208000006029 Cardiomegaly Diseases 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 1
- 208000009889 Herpes Simplex Diseases 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000891649 Homo sapiens Transcription elongation factor A protein-like 1 Proteins 0.000 description 1
- 241000713333 Mouse mammary tumor virus Species 0.000 description 1
- 101000596402 Mus musculus Neuronal vesicle trafficking-associated protein 1 Proteins 0.000 description 1
- 101000800539 Mus musculus Translationally-controlled tumor protein Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 102100028588 Protein ZNRD2 Human genes 0.000 description 1
- 102000009096 Proto-Oncogene Proteins c-myb Human genes 0.000 description 1
- 108010087776 Proto-Oncogene Proteins c-myb Proteins 0.000 description 1
- 101000781972 Schizosaccharomyces pombe (strain 972 / ATCC 24843) Protein wos2 Proteins 0.000 description 1
- 101001009610 Toxoplasma gondii Dense granule protein 5 Proteins 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 108050008367 Transmembrane emp24 domain-containing protein 7 Proteins 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 108010006025 bovine growth hormone Proteins 0.000 description 1
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 description 1
- 229940100084 cardioplegia solution Drugs 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 210000001147 pulmonary artery Anatomy 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000005030 transcription termination Effects 0.000 description 1
- 230000002463 transducing effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Cardiology (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- Pharmacology & Pharmacy (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Vascular Medicine (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hospice & Palliative Care (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11392398P | 1998-12-28 | 1998-12-28 | |
| US60/113923 | 1998-12-28 | ||
| PCT/US1999/031093 WO2000038518A1 (en) | 1998-12-28 | 1999-12-28 | Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2394200A AU2394200A (en) | 2000-07-31 |
| AU763049B2 true AU763049B2 (en) | 2003-07-10 |
Family
ID=22352321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU23942/00A Ceased AU763049B2 (en) | 1998-12-28 | 1999-12-28 | Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1139751A4 (https=) |
| JP (1) | JP2002533359A (https=) |
| AU (1) | AU763049B2 (https=) |
| CA (1) | CA2356551A1 (https=) |
| WO (1) | WO2000038518A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7745416B2 (en) * | 1995-04-11 | 2010-06-29 | The Regents Of The University Of California | Method for in vivo regulation of cardiac muscle contractility |
| CA2389524A1 (en) * | 1999-11-05 | 2001-05-17 | The Regents Of The University Of California | Techniques and compositions for treating cardiovascular disease by in vivo gene delivery |
| CA2419245A1 (en) * | 2000-08-17 | 2002-02-21 | Keiya Ozawa | Adeno-associated virus-mediated delivery of angiogenic factors |
| EP1870473A1 (en) * | 2000-08-17 | 2007-12-26 | Keiya Ozawa | Adeno-associated virus-mediated delivery of angiogenic factors |
| EP1324780A4 (en) | 2000-09-06 | 2005-06-22 | Univ Johns Hopkins | METHODS OF TREATING CARDIAC ARRHYTHMIA |
| WO2002098432A1 (en) * | 2001-06-01 | 2002-12-12 | The Brigham And Women's Hospital, Inc. | Methods of treating cardiac disorders |
| AU2003299204A1 (en) | 2002-10-02 | 2004-04-23 | The Johns Hopkins University | Focal calcium channel modulation |
| US20070134204A1 (en) * | 2005-12-09 | 2007-06-14 | Henrich Cheng | Method for treating nerve injury and vector construct for the same |
| KR20090035711A (ko) * | 2006-07-25 | 2009-04-10 | 셀라돈 코포레이션 | 유전자 치료를 위한 아데노-관련 바이러스 벡터의 전방 심외막 관상에의 연장 주입 |
| KR20100129295A (ko) | 2008-02-19 | 2010-12-08 | 셀라돈 코포레이션 | 심근 내 바이러스 벡터의 흡수를 개선시키기 위한 조성물 |
| AU2012258525B2 (en) * | 2011-05-26 | 2017-02-23 | University Of Washington | Cell and gene based methods to improve cardiac function |
| WO2019097001A1 (en) * | 2017-11-16 | 2019-05-23 | Universite D'aix-Marseille | Fgf10 for the treatment of heart diseases |
| US12460226B2 (en) | 2018-04-16 | 2025-11-04 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating duchenne muscular dystrophy |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792483A (en) * | 1993-04-05 | 1998-08-11 | Vickers, Inc. | Injection molding machine with an electric drive |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6162796A (en) * | 1995-09-27 | 2000-12-19 | The Rockefeller University | Method for transferring genes to the heart using AAV vectors |
-
1999
- 1999-12-28 AU AU23942/00A patent/AU763049B2/en not_active Ceased
- 1999-12-28 CA CA002356551A patent/CA2356551A1/en not_active Abandoned
- 1999-12-28 EP EP99967703A patent/EP1139751A4/en not_active Ceased
- 1999-12-28 JP JP2000590483A patent/JP2002533359A/ja active Pending
- 1999-12-28 WO PCT/US1999/031093 patent/WO2000038518A1/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5792483A (en) * | 1993-04-05 | 1998-08-11 | Vickers, Inc. | Injection molding machine with an electric drive |
Non-Patent Citations (2)
| Title |
|---|
| GNATENKO ET AL. JRN INVESTI MEDICINE 1997,VOL.45(2),P.87-98 * |
| KAPLITT ET AL. ANLS THORACIC SURGERY,1996,VOL.62,P.1669-1676 * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2000038518A1 (en) | 2000-07-06 |
| WO2000038518A9 (en) | 2002-04-11 |
| EP1139751A4 (en) | 2003-03-19 |
| CA2356551A1 (en) | 2000-07-06 |
| EP1139751A1 (en) | 2001-10-10 |
| JP2002533359A (ja) | 2002-10-08 |
| AU2394200A (en) | 2000-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7078387B1 (en) | Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors | |
| CN1136920C (zh) | 基因转移介导的血管形成疗法 | |
| US6936243B2 (en) | Adeno-associated viral vector-mediated delivery of DNA to cells of the liver | |
| US5792453A (en) | Gene transfer-mediated angiogenesis therapy | |
| US20060292117A1 (en) | Improved rAAv vectors | |
| JP2004313198A (ja) | 心筋及び血管平滑筋へのアデノウイルス介在遺伝子移入 | |
| AU763049B2 (en) | Efficient and stable (in vivo) gene transfer to cardiomyocytes using recombinantadeno-associated virus vectors | |
| US20020159978A1 (en) | Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions | |
| EP1053025A2 (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| AU2002226400B2 (en) | Sequences upstream of the carp gene, vectors containing them and uses thereof | |
| Schirmer et al. | Recombinant adeno‐associated virus vector for gene transfer to the transplanted rat heart | |
| AU2002226400A1 (en) | Sequences upstream of the carp gene, vectors containing them and uses thereof | |
| US20060099183A1 (en) | Use of recombinant adeno-associated virus vector (rAAV) for the prevention of smooth muscle cell proliferation in a vascular graft | |
| AU706050C (en) | Gene transfer-mediated angiogenesis therapy | |
| HK1094944A (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| AU2006200170A1 (en) | Combination of a nucleic acid and a vasoactive agent for enhanced gene delivery | |
| AU4754199A (en) | Gene transfer-mediated angiogenesis therapy | |
| AU2006235836A1 (en) | Gene transfer-mediated angiogenesis therapy |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |